Retinyl Propionate, Climbazole Improves Photodamaged Skin

This article originally appeared here.
Share this content:
Retinyl Propionate, Climbazole Improves Photodamaged Skin
Retinyl Propionate, Climbazole Improves Photodamaged Skin

FRIDAY, July 28, 2017 (HealthDay News) -- Retinyl propionate and climbazole (RPC) is associated with clinical improvement in moderately photodamaged skin for women aged 40 to 70 years, according to a study published online July 22 in the International Journal of Cosmetic Science.

Stacy Hawkins, Ph.D., and colleagues from Unilever Research and Development in Trumbull, Conn., and colleagues recruited 45 healthy Caucasian women, ages 40 to 70 years, with moderately photodamaged skin for a 16-week randomized facial study. Using split-face product application, the authors compared the efficacy of RPC treatment with 0.1 percent retinol, in the same product base formulation, twice daily.

The researchers found that, compared to 0.1 percent retinol treatment, RPC treatment correlated with significant improvement in aging attributes (P < 0.05), with minimal irritation. After five weeks of product application, more than 50 percent of subjects showed improvement of deep wrinkles in the crow's feet area; continued improvement was seen throughout the study. The appearance of lines and wrinkles in the nasolabial fold also improved, as did mottled hyperpigmentation. Subjective self-assessment results confirmed in vivo clinical assessments. Significantly less irritation was seen for the RPC product versus the 0.1 retinol product in a separate patch study.

"RPC delivered significant skin antiaging benefits comparable or greater than 0.1 percent retinol, with minimal irritation," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »